BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 17, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorSee today's BioWorld Science
Home » Soluble BCMA-based Fc fusion proteins trapping APRIL and BAFF to treat B-cell malignancies
To read the full story, subscribe or sign in.

Soluble BCMA-based Fc fusion proteins trapping APRIL and BAFF to treat B-cell malignancies

Aug. 23, 2022
A proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF) are two ligands of the tumor necrosis factor (TNF) superfamily with a crucial regulatory role in B-cell maturation and differentiation. APRIL and BAFF action occurs through binding to three TNF receptors: TACI (transmembrane activator and Ca2+ modulator interactor), B-cell maturation antigen (BCMA), and BAFF receptor (BAFF-R) with different affinities.
BioWorld Science Cancer

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 17, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 17, 2025.
  • Art concept for bladder

    Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

    BioWorld
    During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
  • Telomeres and DNA illustration

    23andme founder-led group outbids Regeneron for company

    BioWorld
    The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
  • Sarepta signage

    Elevidys’ second liver death hits Sarepta, sends DMD ripples

    BioWorld
    How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing